Found: 9
Select item for more details and to access through your institution.
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 8, p. 749, doi. 10.3390/ph14080749
- By:
- Publication type:
- Article
Plasticity of Naturally Occurring Regulatory T Cells in Allergic Airway Disease Is Modulated by the Transcriptional Activity of Il-6.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 9, p. 4582, doi. 10.3390/ijms22094582
- By:
- Publication type:
- Article
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
- Published in:
- PLoS ONE, 2024, v. 19, n. 4, p. 1, doi. 10.1371/journal.pone.0298808
- By:
- Publication type:
- Article
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-38933-4
- By:
- Publication type:
- Article
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.642328
- By:
- Publication type:
- Article
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
- Published in:
- Cell Death & Disease, 2020, v. 11, n. 6, p. 1, doi. 10.1038/s41419-020-2646-2
- By:
- Publication type:
- Article
Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles.
- Published in:
- PLoS ONE, 2022, v. 17, n. 3, p. 1, doi. 10.1371/journal.pone.0265852
- By:
- Publication type:
- Article
Molecular networks in atopic mothers impact the risk of infant atopy.
- Published in:
- Allergy, 2023, v. 78, n. 1, p. 244, doi. 10.1111/all.15490
- By:
- Publication type:
- Article
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
- Published in:
- Breast Cancer Research, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13058-024-01799-5
- By:
- Publication type:
- Article